Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Gert J. Meijer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5408-2094; OpenAlex author ID A5028860020. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 5 papers · 2025: 2 papers · 2026: 3 papers

Papers 18

  1. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  2. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  3. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  4. Quality of Life and Toxicity in Patients With Pancreatic Ductal Adenocarcinoma Treated With Online Adaptive Stereotactic Magnetic Resonance Guided Radiation Th… Co-author DOI 10.1016/j.ijrobp.2025.03.046↗
  5. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  6. Radiation response assessment of organoids derived from patients with pancreatic cancer. Co-author DOI 10.1016/j.ctro.2024.100829↗
  7. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  8. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  9. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  10. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  11. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Co-author DOI 10.1186/s13063-022-07036-8↗
  12. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Co-author DOI 10.1097/sla.0000000000004093↗
  13. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARC… Co-author DOI 10.1186/s13063-022-06829-1↗
  14. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  15. MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Last author DOI 10.1259/bjr.20170563↗
  16. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. Co-author DOI 10.1016/j.prro.2016.10.006↗
  17. Probabilistic treatment planning for pancreatic cancer treatment: prospective incorporation of respiratory motion shows only limited dosimetric benefit. Last author DOI 10.1080/0284186x.2016.1257863↗
  18. MRI-based tumor motion characterization and gating schemes for radiation therapy of pancreatic cancer. Last author DOI 10.1016/j.radonc.2014.03.002↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martijn Intven · 15 shared papers, 2018–2026 · strength 2.33
  2. Lois A. Daamen · 14 shared papers, 2021–2026 · strength 2.25
  3. Izaak Quintus Molenaar · 14 shared papers, 2014–2026 · strength 2.08
  4. Hjalmar C. van Santvoort · 13 shared papers, 2014–2026 · strength 1.99
  5. Marc G. Besselink · 11 shared papers, 2022–2026 · strength 1.76
  6. Iris W.J.M. van Goor · 10 shared papers, 2022–2026 · strength 1.64
  7. Robert C. Verdonk · 9 shared papers, 2022–2026 · strength 1.49
  8. Vincent Erwin de Meijer · 9 shared papers, 2022–2026 · strength 1.49
  9. Ignace H. J. T. de Hingh · 9 shared papers, 2022–2026 · strength 1.49
  10. Martijn W.J. Stommel · 9 shared papers, 2022–2026 · strength 1.49
  11. Bas Groot Koerkamp · 8 shared papers, 2022–2026 · strength 1.26
  12. Hanne D. Heerkens · 10 shared papers, 2014–2026 · strength 1.13
  13. Bert A. Bonsing · 6 shared papers, 2024–2026 · strength 1.09
  14. Paul C. M. Andel · 6 shared papers, 2024–2026 · strength 1.03
  15. Vincent B. Nieuwenhuijs · 6 shared papers, 2022–2026 · strength 0.99
  16. Sebastiaan Festen · 6 shared papers, 2022–2026 · strength 0.99
  17. Geert Kazemier M · 6 shared papers, 2022–2026 · strength 0.99
  18. Vincent P. Groot · 6 shared papers, 2022–2026 · strength 0.99
  19. Johanna W. Wilmink · 5 shared papers, 2022–2026 · strength 0.77
  20. Hanneke W.M. van Laarhoven · 5 shared papers, 2022–2026 · strength 0.77
  21. Nadia Haj Mohammad · 5 shared papers, 2022–2024 · strength 0.67
  22. Lodewijk A.A. Brosens · 4 shared papers, 2024 · strength 0.64
  23. Geertjan van Tienhoven · 5 shared papers, 2017–2024 · strength 0.63
  24. Thijs J. Schouten · 3 shared papers, 2024–2026 · strength 0.56
  25. Anna M E Bruynzeel · 3 shared papers, 2022–2026 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.